Sterling to make API in flow process

The pharmaceutical services provider Sterling Pharma Solutions will produce hypericin, the active ingredient in an oncology drug being developed by the biotech firm Soligenix. Sterling says it will conduct the synthesis at its plant in Germantown, Wisconsin. The synthesis will include a photocatalyzed intramolecular cyclization reaction that takes place in a flow reactor built by the German firm Peschl Ultraviolet. Hypericin is applied as an ointment to cutaneous T-cell lymphoma lesions and then activated by fluorescent light.